Comprehensive analysis covering market share, industry trends, growth drivers, opportunities, and forecasts for the global Next Generation Sequencing (NGS) product market from 2020 to 2035.
The economic impact of tariffs on "Global Next Generation Sequencing (NGS) Product".
Market Growth Drivers
Increased adoption of personalized medicine has driven the demand for NGS products globally. Companies like Illumina have been at the forefront by partnering with pharmaceutical companies to accelerate research in targeted therapies using NGS. As more healthcare providers embrace precision medicine, the need for accurate, high-throughput sequencing solutions expands, further propelling market growth.
Technological advancements such as improved sequencing speed and reduced costs are fostering greater market penetration. For example, Thermo Fisher Scientific introduced new benchtop sequencers that deliver whole genome sequencing at a fraction of previous costs. This has made NGS accessible for smaller research labs, clinical diagnostics, and new therapeutic areas, broadening the overall application range.
Key Market Trends
Integration of artificial intelligence (AI) for data analysis in NGS workflows is becoming increasingly prevalent. Companies like Oxford Nanopore Technologies are leveraging AI-based systems for faster, more accurate data interpretation, thus reducing turnaround times and improving scalability for clinical and research applications.
Expansion into non-invasive diagnostic markets, particularly liquid biopsy, is transforming the use of NGS in oncology. Guardant Health and Roche have developed NGS assays for circulating tumor DNA, enabling early cancer detection and monitoring with minimally invasive procedures. These trends are reshaping both clinical workflows and patient outcomes worldwide.
Market Opportunities
Emerging markets such as India, Brazil, and Southeast Asia present significant opportunities for NGS adoption due to rising healthcare expenditure and government support for genomics research. Companies like BGI are investing heavily in these regions to localize manufacturing and offer customized sequencing solutions.
The development of NGS-based companion diagnostics for immunotherapy drugs presents a high-growth opportunity. Partnerships between genomics firms and pharmaceutical companies, like Illumina's collaboration with Merck, aim to co-develop regulatory-approved tests to optimize drug-patient matching.
Global NGS Product Market Revenue (USD Million), 2020-2035
The chart illustrates a robust upward trend in revenue for the global NGS product market over the forecast period. Starting at USD 4,300 Million in 2020, the market demonstrates consistent year-on-year growth, fueled by technological advancements, expanding clinical applications, and global market penetration. By 2025, revenue reaches approximately USD 8,700 Million, and by 2035, it is projected to grow sharply to USD 35,800 Million. The compound annual growth rate (CAGR) is estimated at nearly 14.2% between 2024 and 2035, reflecting aggressive investments in innovation, greater access in emerging economies, and the rise of precision medicine driving market acceleration.
Global NGS Product Market Share by Region (%) - 2025
The pie chart for 2025 displays a dominant market share held by North America at 41%, reflecting advanced healthcare infrastructure and significant R&D investments. Europe accounts for 26%, driven by widespread clinical adoption and favorable regulatory support. Asia-Pacific commands 23% market share, buoyed by rapid technological deployment in China, Japan, and India. Latin America holds a 6% share, while the Middle East & Africa together comprise 4%. The data indicates that while North America remains the leader, Asia-Pacific is expected to witness faster year-on-year growth due to rising healthcare investments and expanding population bases.
Recent Developments (Last 6 Months)
In April 2024, Illumina launched the NovaSeq X Plus, featuring ultra-high throughput and reduced sequencing costs per genome. This new platform enables large-scale population genomics studies and further expands the scalability of clinical sequencing for healthcare providers globally.
In February 2024, Thermo Fisher Scientific announced a strategic collaboration with AstraZeneca to co-develop NGS-based companion diagnostics for oncology therapeutics. The partnership aims to accelerate regulatory approvals and broaden access to personalized cancer treatments through new, clinically validated sequencing assays.
In May 2024, BGI Genomics expanded its presence in Latin America by establishing a new manufacturing facility in Brazil. The move is anticipated to significantly cut costs and delivery times for NGS products in the region, supporting local genomics research and diagnostics initiatives.
Press Releases